CONTRÔLE ET MODULATION DE LA FONCTION DE LYMPHOCYTES T À RÉCEPTEUR D'ANTIGÈNE CHIMÉRIQUE GÉNETIQUEMENT MODIFIÉS AVEC DU DASATINIB ET D'AUTRES INHIBITEURS DE TYROSINE KINASE

• 收藏
• 分享

专利权人:

Julius-Maximilians-Universität Würzburg

发明人:

申请号：

EP18811588.5

公开号：

EP3720477A1

申请日:

2018.12.07

申请国别(地区):

EP

年份:

2020

代理人:

摘要：

The invention relates to the immunomodulatory features of dasatinib and other tyrosine kinase inhibitors towards genetically modified immune cells. The invention encompasses the indication of dasatinib and other tyrosine kinase inhibitors as an immune cell inhibitor as well as an enhancer of immune cells depending on the dosing and schedule of treatment, the administration routes, the susceptible receptor variants and the treatable cell types which can be used for immunotherapy.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/